Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

Hammock faced two major obstacles: financing and moving the drug into clinical trials.

"Finding resources in an academic laboratory to move a first-in-class drug through clinical trials, is difficult," Hammock said. "It costs $700 million to $1.2 billion to get a treatment to the market."

"Publicly funded research," the professor said, "results in many new possible pharmaceutical targets that could be exploited by either small molecule drugs or biotechnology. However, society faces a serious problem in that few of these leads are followed and there is a widely held view that universities cannot validate a target, much less optimize a pharmaceutical."

So in 2002, Hammock founded the biotech company, Arte Therapeutics, Inc., naming the company a mountaineering term that means "sharp, steep ridge." Specifically, the company is named for the artes of the Bear Creek Spire of the Sierra Nevada that he, his sons and occasionally other UC Davis faculty and students climb.

"The artes that climbers follow to peaks are often inspiring as well as challenging," Hammock said. "I founded the company because I failed to transfer technology to the public from the University of California by other means in the past," Hammock said. "And I received nothing more than a passing interest from pharmaceutical companies at that time, but now they are very interested."

In 2003, he and his son, also named Bruce, incorporated the company to move the materials into clinical trials. "To get funding we had to make a case for a new drug when current therapy was thought to be adequate," the professor said. "There are few good drugs for end organ failure and vascular inflammation." Vascular inflammation is involved in diabetes and obesity side effects.

"The collaborative and interdisciplinary environment at UC Davis permitted us, with support from the National Institute of Environmental Health Sciences, to optimize the potency and drug
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:10/19/2014)... India over the last 30 years contributed only ... during that time, according to a new study ... ., "Energy access is fundamental to development: it ... education, communication, and health," says IIASA researcher Shonali ... energy access is widely agreed to be an ...
(Date:10/17/2014)... Why do male ... reproduce? And why are there two sexes anyway? These and ... the research journal Molecular Human Reproduction published today ... University Bielefeld has compiled this special issue on sperm competition. ... copulate with several males in quick succession – chimpanzees are ...
(Date:10/16/2014)... a new synthesis of recent research findings to inform ... the two states. , The Ecology and Management ... A Synthesis of the Relevant Biophysical Science and Implications ... by the U.S. Forest Service,s Pacific Northwest Research Station, ... for a synthesis of the large body of scientific ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... in cells in precise detail like never before. This provides ... The breakthrough study, conducted by Sean Humphrey and ... is now published in the early online edition of the ... 1921, the insulin hormone plays a very important role in ...
... commonly resistant to antimicrobial substances made by the human ... the online open-access journal of the American Society for ... lysozyme, which help defend the body against bacterial attack, ... are also saddled with a crippled immune response. Colistin ...
... Amazon rain forest, popularly known as the lungs of the ... carbon dioxide from the air to grow parts that eventually ... by the region,s plentiful rainfall. Until recently people ... Amazon River and ended up deep in the ocean. University ...
Cached Biology News:Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
(Date:10/22/2014)... Involution Studios , a healthcare ... new infographic, Understanding Ebola . The goal ... easy to follow informative tool for anyone wanting to ... and prevention. , "As the news has spread in ... outbreak represents not only a healthcare crisis with global ...
(Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
(Date:10/22/2014)... KONG , Oct. 22, 2014  aTyr Pharma ... that rare disease expert John C. McKew , ... McKew brings more than two decades of expertise in ... Institutes of Health, Wyeth Research and Genetics Institute, Inc. ... aTyr,s efforts to expand and translate its novel Physiocrine ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... , , , ... (Nasdaq: SQNM ) and GeneWorks Pty. Ltd. today ... assist SEQUENOM in expanding its sales & marketing presence in ... activity across Australia. GeneWorks has significant experience and a strong ...
... N.Y., Sept. 9 Misonix, Inc. (Nasdaq: ... device technology, which in Europe is used for the ... conditions, has entered into a new, two year, sales ... Bangalore, India. Novotech will serve as the sales and ...
... , , ANN ARBOR, Mich., Sept. 9 ... $137,500 in micro loan funding through the Michigan Pre-Seed Capital ... growth throughout the state. Advanced Battery Concepts, FreeStride and ... of their technologies. , , "Helping companies ...
Cached Biology Technology:SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia 2SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia 3SEQUENOM Announces Partnership With GeneWorks for Sales & Marketing of MassARRAY Systems and Applications in Australia 4Misonix Announces New Sales Agency Agreement for Middle East, India and Pakistan 2Misonix Announces New Sales Agency Agreement for Middle East, India and Pakistan 3Michigan Pre-Seed Capital Fund Awards Three Micro Loans 2
... for maximum packaging efficiencies of T7Select vectors ... (> 109 pfu/g with control DNA) make ... at least 5 107 recombinant plaques ... from a specially designed phage that reduces ...
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
...
Biology Products: